Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2012

01.11.2012 | Gynecologic Oncology

Neuroendocrine tumor of the uterine cervix: a clinicopathologic study of 14 cases

verfasst von: Peng Peng, Wu Ming, Yang Jiaxin, Shen Keng

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The study explored the clinicopathologic characteristics of the neuroendocrine tumor of uterine cervix (NTUC).

Methods

The general information and the clinical–pathological characteristics of 14 NTUC cases were reviewed.

Results

The median age of the cases was 41 years. Six cases (42.9 %) were FIGO stage Ib1, four cases (28.6 %) were Ib2, one case was IIa2 (7.1 %), one case (7.1 %) was IIb, one case (7.1 %) was IIIb and one case (7.1 %) was IVb. Radical hysterectomy and bilateral salpingo-oophorotomy plus pelvic lymphadenectomy were performed on seven cases: three cases had radical hysterectomy plus pelvic lymphadenectomy; one case had transabdominal hysterectomy; and one case had a residual cervical resection. Four cases had positive pelvic lymph nodes. Two cases (14.3 %) had the tumor infiltrated to the parametrium and five cases (35.7 %) to lymphovascular space. One case had positive margin of vagina. Nine cases (64.3 %) were administered post-surgery radiotherapy and all cases were given adjuvant chemotherapy. The median follow-up time was 10 months. The median disease-free survival was 6 months, and the median total survival time was 18 months. The median estimated survival time was 32.0 months (95 % CI 16.9–47.1 months).

Conclusions

NTUC is a very rare malignant tumor of female genital tract. Multi-center cooperation to gather more cases is the best method to explore the biological behavior and for the proper treatment of NTUC.
Literatur
2.
Zurück zum Zitat Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, Scully RE, Silva E, Sobin LH, Tavassoli FJ, Travis WD, Woodruff JM (1997) Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 121(1):34–39PubMed Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, Scully RE, Silva E, Sobin LH, Tavassoli FJ, Travis WD, Woodruff JM (1997) Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med 121(1):34–39PubMed
3.
Zurück zum Zitat Albores- Saavedra J, Poucell S, Rodriguez- Martinez HA (1972) Primary carcinoid of the uterine cervix. Patologia 10:185–193 Albores- Saavedra J, Poucell S, Rodriguez- Martinez HA (1972) Primary carcinoid of the uterine cervix. Patologia 10:185–193
4.
Zurück zum Zitat Wang KL, Yang YC, Wang TY, Chen JR, Chen TC, Chen HS, Su TH, Wang KG (2006) Neuroendocrine carcinoma of the uterine cervix: a clinicopathologic retrospective study of 31 cases with prognostic implications. J Chemother 18(2):209–216PubMed Wang KL, Yang YC, Wang TY, Chen JR, Chen TC, Chen HS, Su TH, Wang KG (2006) Neuroendocrine carcinoma of the uterine cervix: a clinicopathologic retrospective study of 31 cases with prognostic implications. J Chemother 18(2):209–216PubMed
7.
9.
Zurück zum Zitat Ishida GM, Kato N, Hayasaka T, Saito M, Kobayashi H, Katayama Y, Sasou S, Yaegashi N, Kurachi H, Motoyama T (2004) Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. Int J Gynecol Pathol 23(4):366–372 [pii: 00004347-200410000-00009]PubMedCrossRef Ishida GM, Kato N, Hayasaka T, Saito M, Kobayashi H, Katayama Y, Sasou S, Yaegashi N, Kurachi H, Motoyama T (2004) Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. Int J Gynecol Pathol 23(4):366–372 [pii: 00004347-200410000-00009]PubMedCrossRef
10.
Zurück zum Zitat Ng WK, Cheung LK, Li AS (2003) Thin-layer cytology findings of small cell carcinoma of the lower female genital tract. Review of three cases with molecular analysis. Acta Cytol 47:56–64PubMedCrossRef Ng WK, Cheung LK, Li AS (2003) Thin-layer cytology findings of small cell carcinoma of the lower female genital tract. Review of three cases with molecular analysis. Acta Cytol 47:56–64PubMedCrossRef
11.
Zurück zum Zitat Ciesla MC, Guidos BJ, Selvaggi SM (2001) Cytomorphology of small-cell (neuroendocrine) carcinoma on ThinPrep cytology as compared to conventional smears. Diagn Cytopathol 24:46–52PubMedCrossRef Ciesla MC, Guidos BJ, Selvaggi SM (2001) Cytomorphology of small-cell (neuroendocrine) carcinoma on ThinPrep cytology as compared to conventional smears. Diagn Cytopathol 24:46–52PubMedCrossRef
12.
Zurück zum Zitat Kim Y, Ha HJ, Kim JS et al (2002) Significance of cytologic smears in the diagnosis of small cell carcinoma of the uterine cervix. Acta Cytol 46:637–644PubMedCrossRef Kim Y, Ha HJ, Kim JS et al (2002) Significance of cytologic smears in the diagnosis of small cell carcinoma of the uterine cervix. Acta Cytol 46:637–644PubMedCrossRef
13.
Zurück zum Zitat Kataoka TR, Tsukamoto Y, Matsumura M, Miyake A, Kamiura S, Ishiguro S, Nishizawa Y (2008) Expression of p21Cip1/Waf1 and p27Kip1 in small cell neuroendocrine carcinoma of the uterine cervix. Int J Surg Pathol 16(1):11–15. doi:10.1177/1066896907309574 PubMedCrossRef Kataoka TR, Tsukamoto Y, Matsumura M, Miyake A, Kamiura S, Ishiguro S, Nishizawa Y (2008) Expression of p21Cip1/Waf1 and p27Kip1 in small cell neuroendocrine carcinoma of the uterine cervix. Int J Surg Pathol 16(1):11–15. doi:10.​1177/​1066896907309574​ PubMedCrossRef
14.
Zurück zum Zitat Herrington CS, Graham D, Southern SA, Bramdev A, Chetty R (1999) Loss of retinoblastoma protein expression is frequent in small cell neuroendocrine carcinoma of the cervix and is unrelated to HPV type. Hum Pathol 30(8):906–910PubMedCrossRef Herrington CS, Graham D, Southern SA, Bramdev A, Chetty R (1999) Loss of retinoblastoma protein expression is frequent in small cell neuroendocrine carcinoma of the cervix and is unrelated to HPV type. Hum Pathol 30(8):906–910PubMedCrossRef
15.
16.
Zurück zum Zitat Albores-Saavedra J, Latif S, Carrick KS et al (2005) CD56 reactivity in small cell carcinoma of the uterine cervix. Int J Gynecol Pathol 24:113–118PubMedCrossRef Albores-Saavedra J, Latif S, Carrick KS et al (2005) CD56 reactivity in small cell carcinoma of the uterine cervix. Int J Gynecol Pathol 24:113–118PubMedCrossRef
17.
Zurück zum Zitat Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB (2008) Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol 19(2):321–326. doi:10.1093/annonc/mdm465 PubMedCrossRef Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB (2008) Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol 19(2):321–326. doi:10.​1093/​annonc/​mdm465 PubMedCrossRef
20.
22.
Zurück zum Zitat Yu A, Zhang P, Lou H (2002) Clinicophathologic characteristics and treatment of small cell carcinoma of uterine cervix. Zhonghua Zhong Liu Za Zhi 24(4):400–403PubMed Yu A, Zhang P, Lou H (2002) Clinicophathologic characteristics and treatment of small cell carcinoma of uterine cervix. Zhonghua Zhong Liu Za Zhi 24(4):400–403PubMed
23.
24.
Zurück zum Zitat Lee SS, Lee JL, Ryu MH (2007) Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol 46:846–851PubMedCrossRef Lee SS, Lee JL, Ryu MH (2007) Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol 46:846–851PubMedCrossRef
25.
27.
Zurück zum Zitat Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, Lee N (2003) Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 21(18):3495–3501. doi:10.1200/JCO.2003.01.501 PubMedCrossRef Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, Lee N (2003) Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol 21(18):3495–3501. doi:10.​1200/​JCO.​2003.​01.​501 PubMedCrossRef
Metadaten
Titel
Neuroendocrine tumor of the uterine cervix: a clinicopathologic study of 14 cases
verfasst von
Peng Peng
Wu Ming
Yang Jiaxin
Shen Keng
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2012
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2407-2

Weitere Artikel der Ausgabe 5/2012

Archives of Gynecology and Obstetrics 5/2012 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.